Cramer's Mad Dash: Moderna gets upgrade from HSBC
CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...
The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week
Big pharma stocks needed a shot in the arm after Donald Trump chose vaccine skeptic Robert F. Kennedy Jr. as health secretary ...
Seeking Alpha on MSN1h
BioNTech started at buy, Moderna at hold by Berenberg
Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...
Moderna initiated with a Hold at Berenberg
Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...
Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
Inside Moderna’s Tech-Driven Culture: Insights From CIO Brad Miller
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...
Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler
Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...
FiercePharma12d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Demystifying Moderna: Insights From 16 Analyst Reviews
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...
Moderna, Pfizer Stocks Fall After Reports of RFK Jr. Nomination
Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr.